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OBJECTIVES We sought to assess the fate of stent (ST)-related side branches (SB) after coronary
intervention in patients with in-ST restenosis.
BACKGROUND In-ST restenosis constitutes a therapeutic challenge. Although the fate of lesion-related SB
after conventional angioplasty or initial coronary stenting is well established, the outcome of
ST-related SB in patients with in-ST restenosis undergoing repeat intervention is unknown.
METHODS One hundred consecutive patients (age 61 6 11 years, 22 women) undergoing repeat
intervention for in-ST restenosis (101 ST) were prospectively studied. Two hundred and
twenty-six SB spanned by the ST were identified. The SB size, type, ostium involvement,
location within the ST and take-off angle were evaluated. The SB TIMI (Thrombolysis in
Myocardial Infarction trial) flow grade was studied in detail before, during, immediately after
the procedure, and at late angiography.
RESULTS Occlusion (TIMI flow grade 5 0) was produced in 24 (10%) SB, whereas some degree of flow
deterioration ($1 TIMI flow grade) was observed in 57 SB (25%). The SB occlusion was
associated with non–Q wave myocardial infarction in two patients (both had large and
diseased SB). Side-branch occlusion at the time of initial stenting (RR [relative risk] 11.1,
95% CI [confidence interval] 3.5–35.5, p , 0.001), diabetes (RR 3.5, 95% CI 1.1–10.5, p 5
0.02), SB ostium involvement (RR 5.0, 95% CI 1.4–17.2, p 5 0.004), baseline SB TIMI flow
grade ,3 (RR 5.5, 95% CI 1.7–18.1, p 5 0.005), and restenosis length (RR 1.05 95% CI
1.01–1.11, p 5 0.03) were identified as independent predictors of SB occlusion. Late
angiography in 19 initially occluded SB revealed that 17 (89%) were patent again. The
long-term clinical event-free survival (81% vs. 82% at two years) in patients with and without
initial SB occlusion was similar.
CONCLUSIONS Occlusion or flow deterioration of SB spanned by the ST is relatively common during repeat
intervention for in-ST restenosis. Several factors (mainly anatomic features) are useful
predictors of this event. However, most SB occlusions are clinically silent and frequently
reappear at follow-up. (J Am Coll Cardiol 2000;36:1549–56) © 2000 by the American
College of Cardiology
Coronary stenting is the most frequently used technique
today during coronary interventions (1–5). The implanta-
tion of stents (ST) has experienced an exponential increase
after some technical and pharmacological refinements have
dramatically improved procedural results (3,4). Multiple
customized ST designs currently allow the treatment of a
wide spectrum of coronary lesions, including those with
untoward anatomical features (1–5). However, in-ST re-
stenosis is being increasingly recognized as a challenging
clinical problem affecting a growing number of patients
(6–13). Different strategies (balloon angioplasty, debulking
techniques, brachytherapy and repeat stenting) are currently
advocated for the treatment of these patients, yet the
procedure of choice remains elusive (6–13). In addition, the
outcome of lesion-associated side branches (SB) after con-
ventional angioplasty (14,15) or coronary stenting (16–23)
is well established. Nevertheless, the fate of ST-related SB
in patients with in-ST restenosis undergoing repeat coro-
nary intervention remains unsettled. Accordingly, the
present prospective study was undertaken to assess the
incidence, predictive factors and implications of SB occlu-
sion in patients treated for in-ST restenosis.
METHODS
Patient group. From November 1991 to June 1998, a total
of 100 consecutive patients with in-ST restenosis (101 ST)
underwent repeat coronary interventions in our hospital. All
these patients had angina or objective evidence of ischemia.
The characteristics and fate of the 226 SB spanned by these
ST were analyzed.
Procedure and protocol. Both the protocol and the tech-
nique of coronary stenting in our center have been previ-
ously described in detail (5,24). Briefly, balloon catheters
and the ST type at the time of initial stenting were selected
at the discretion of the primary operator. Since 1994,
relatively high pressures ($12 atm) have been systematically
used, and this policy was coincident with the use of both
aspirin and ticlopidine on a routine basis. Several types of
ST with restenosis were treated: Palmaz-Schatz ST (John-
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son & Johnson Interventional Systems, Warren, New Jer-
sey) (n 5 25); Gianturco-Roubin Flex-ST (Cook, Bloom-
ington, Indiana) (n 5 25); NIR ST (Boston Scientific,
Maple Grove, Minnesota) (n 5 22); Multilink ST (ACS,
Guidant, Temecula, California) (n 5 10), and other types
(n 5 19). Patients with in-ST restenosis involving saphe-
nous vein grafts were excluded from the study. Our
follow-up protocol in patients undergoing coronary stenting
included clinical assessment at one and six months and
yearly thereafter, in a specific clinic devoted to patients with
percutaneous coronary interventions. In these visits an
exercise test (or alternative tests to elicit ischemia) was
scheduled.
Our protocol of repeat angioplasty for patients with
in-ST restenosis has also been reported elsewhere (9). All
patients signed written, informed consent for the procedure.
Balloon size and inflation pressure were left to the discretion
of the primary operator after reviewing those used during
initial ST implantation. As a general rule, pressures similar
to those employed during initial stenting were selected, as
was a balloon-to-artery ratio of 1.1:1. In some cases,
including some patients with diffuse in-ST restenosis, de-
bulking/facilitating techniques or even repeat stenting pro-
cedures were indicated according to the criteria of the
primary operator. If repeat stenting was selected, coil
designs were avoided whenever possible. Most patients
undergoing “elective” repeat stenting were included in a
pilot study assessing the results of this strategy (25). Aspirin
was the only antiplatelet agent systematically used after the
procedure except in patients undergoing repeat stenting,
who also received ticlopidine. Serial (every 8 h) enzyme
measurements and 12-lead electrocardiograms (ECGs)
were obtained during the first 24 h in all patients. A careful
clinical follow-up was performed, and telephone contact
with the patient or referring physician was attempted for
those patients who did not return for follow-up.
In addition, all these patients were asked to return for
routine late angiography (six to nine months). Nevertheless,
this protocol was made flexible in selected patients (multiple
interventions, vascular access difficulties, etc.) when they
expressed reluctance to late angiography and they were
asymptomatic and ischemia-free at follow-up. During
follow-up, clinical events were defined as myocardial infarc-
tion, requirement for target vessel revascularization, or
death. The diagnosis of myocardial infarction required two
of the following: 1) typical, prolonged (.30 min) precordial
pain; 2) development of abnormal Q waves; and 3) creati-
nine kinase increase $2 times the upper normal value. All
this information was prospectively entered in our dedicated,
relational database.
Angiographic analysis. Detailed qualitative analyses were
performed jointly by two experienced observers who were
blinded to the procedure information. Lesion characteristics
were established using different projections (24–26). Care
was taken in trying to identify, on fluoroscopy, the site of
ST deployment in each projection before the injection of
contrast material. This was subsequently related to the exact
location of the restenosis narrowing and SB location.
Vessels with a Thrombolysis in Myocardial Infarction
(TIMI) flow grade 0 (27) were classified as occluded. The
modified American College of Cardiology/American Heart
Association (ACC/AHA) criteria were also used to classify
the morphology of the in-ST restenosis lesion (26). In
addition, lesions .10 mm in length were considered diffuse
restenosis. For the purposes of the present study, special care
was taken to identify and classify all ST-related SB (as
visualized just before treatment of in-ST restenosis). Any
SB that was incorporated within the longitudinal confines of
the ST (bridged by the ST) was analyzed.
Side branches were divided into those emerging from
within the ST body and those located near (#3 mm) the ST
edges. A take-off angulation ,45° or .135° from the parent
vessel was considered unfavorable (at risk for occlusion).
The SB were further assessed for the presence of ostial
narrowing (mild 25% to 50%, moderate 50% to 75%, severe
.75%). A previously reported classification of SB (17) was
followed. Briefly, SB were classified as type A ($1 mm in
diameter with ostial narrowing), type B ($1 mm in diam-
eter, without ostial involvement), type C (,1 mm in
diameter with ostial narrowing), and type D (,1 mm in
diameter without ostium narrowing). The TIMI flow of the
ST-related SB was assessed before and after the procedure.
When different adjunctive or synergistic devices were used,
the exact temporal relation to SB changes was recorded. In
addition, SB changes during repeat intervention for in-ST
restenosis were correlated to the SB changes that had
previously occurred at the time of initial ST implantation.
Matching angiographic views were reviewed before inter-
vention, following initial balloon dilation, following specific
device (when used), immediately after the procedure and at
follow-up.
Quantitative angiographic analysis was carried out off-line
by an experienced operator who was blinded to the patient’s
clinical or procedural characteristics. A commercially avail-
able, previously validated, interactive, automatic edge-
detection algorithm (ARTREK, Quantim 2000I, QCS,
ImageComm Systems) was used (5,17,24). Cine sequences
displaying the most severe lumen narrowing, without fore-
shortening of the selected coronary segment, were selected
from among multiple projections. End-diastolic cine frames
were selected from a Tagarno 35AX and were digitized with
a high-quality cine-video converter. Quantitative analysis
was performed in the stented (trunk) parent vessel.
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
SB 5 side branch(es)
ST 5 stent(s)
TIMI 5 Thrombolysis in Myocardial Infarction
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Statistical analysis. Continuous variables were expressed
as mean 6SD and were compared with the two-tailed
Student t test or the Wilcoxon nonparametric test, as
required. Either the chi-square or Fischer exact test was
used for discrete variables (absolute values and percentages).
Several (18 clinical, 29 procedural and 54 angiographic)
variables were studied in relation to the occurrence of SB
occlusion and SB flow deterioration. In addition, predictors
of SB occlusion or flow deterioration were evaluated with
logistic regression analysis. Factors showing a p value ,0.15
on univariate analysis were entered into the model. Relative
risk (RR) and adjusted RR, with 95% confidence intervals
(CI) were calculated. Likelihood ratios were also calculated.
Rates of event-free survival were studied with Kaplan-Meier
analysis. The Breslow exact test was used to study differ-
ences in event-free survival in patients with and without SB
occlusion. The SPSS for Windows (version 8.0) statistical
software package was used. A p value ,0.05 was considered
statistically significant.
RESULTS
Procedural results. Baseline demographic characteristics
of the 100 study patients are presented in Table 1. Mean age
of the group was 61 6 11 years (range 32 to 82 years) and
22 patients were women. All these patients had angina
(mainly unstable angina) or objective evidence of ischemia.
Most of these patients had good left ventricular ejection
fraction, although a prior history of myocardial infarction
was present in half of them (Table 1). The elapsed time
from initial stenting to repeat intervention was 194 6
111 days. Relevant angiographic data are also summarized
in Table 1. Most ST were located on the left anterior
descending coronary artery, and the restenosis had a relatively
complex morphology. Procedural characteristics at the time
of initial ST implantation and during the index procedure
are displayed in Table 2. Most procedures, 45 (44%) were
performed with balloon dilation alone. The “watermelon
seed” phenomenon was transitorily observed in six patients.
In the remaining patients, including some with diffuse
in-ST restenosis, debulking/facilitating techniques (excimer
Table 1. Baseline Clinical and Angiographic Characteristics
Clinical Data
Age (yrs) 61 6 11
Female gender 22 (22%)
Hypertension 56 (56%)
Hypercholesterolemia 48 (48%)
Diabetes 23 (23%)
Cigarette smoking 68 (68%)
Reason for coronary angioplasty
Stable angina 30 (29%)
Unstable angina 50 (50%)
Acute myocardial infarction 1 (1%)
Silent ischemia 19 (19%)
Previous myocardial infarction 51 (51%)
Previous bypass surgery 5 (5%)
Multivessel disease 50 (50%)
$2 Previous PTCA procedures 31 (31%)
$2 at the target site 20 (20%)
Angiographic Data
Left ventricular ejection fraction (%) 67 6 12
Site of ST restenosis (101 ST)
Left main 2 (2%)
Left anterior descending 61 (60%)
Right 27 (27%)
Left circumflex 11 (11%)
Total occlusion 6 (6%)
ACC/AHA Classification B2-C 80 (80%)
Diffuse restenosis (.10 mm) 71 (71%)
ACC/AHA 5 American College of Cardiology/American Heart Association Clas-
sification; PTCA 5 percutaneous transluminal coronary angioplasty; ST 5 stent.
Table 2. Procedural Data
Complete revascularization* 61 (61%)
During diagnosis† 34 (34%)
Emergency‡ 8 (8%)
Type of procedure§
PTCA alone 45 (44%)
Adjunctive debulking 19 (19%)
Repeat stenting 37 (37%)
Double wire 9 (9%)
Technical data Initial ST Index p Value
Maximal pressure (atm) 10.9 6 3.1 11.5 6 3.0 NS
Balloon diameter (mm) 3.2 6 0.4 3.2 6 0.4 NS
Balloon/artery ratio 1.03 6 0.1 1.07 6 0.1 NS
Reference vessel (mm) 3.1 6 0.4 3.0 6 0.4 NS
Baseline MLD (mm) 0.35 6 0.3 0.51 6 0.3 0.01
Post-PTCA MLD (mm) 2.61 6 0.5 2.37 6 0.5 0.01
Acute gain (mm) 2.24 6 0.83 1.75 6 0.7 0.01
Lesion length (mm) 13.2 6 9.1 14.8 6 9.1 NS
ST length (mm)†† 22.0 6 10 21.1 6 9 NS
ST indication††
Elective 55 (55%) 29 (78%) NS
Unplanned 46 (45%) 8 (35%) NS
PTCA 5 percutaneous transluminal coronary angioplasty; ST 5 stent; MLD 5 miminal lumen diameter. *All major vessels with .70% lumen diameter stenosis. †Ad hoc
angioplasty, during the same diagnostic angiographic procedure. ‡Procedures performed on an urgent basis (i.e., not included in the schedule). §At the discretion of the primary
operator. ††Index procedure only of the 37 patients undergoing stenting.
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laser 5 15; rotablator 5 1; cutting balloon 5 3) and even
repeat stenting (37 patients, 29 [78%] elective, 8 [22%] after
failure or suboptimal result with the primary device) were
used. The ST used during repeat stenting included: NIR ST
(n 5 18), Multilink ST (n 5 10), Crown ST (n 5 4),
Gianturco-Roubin ST (n 5 3), other types (n 5 2).
Angiographic success was obtained in 100 of the 101
(99%) ST. Dilation failure without complications occurred
in one patient. Four patients developed a myocardial infarc-
tion (only one Q wave). The Q wave infarction was
produced after vessel occlusion distal to the treated ST. A
non–Q wave infarction was associated with a SB occlusion
during ST implantation in a de novo lesion in another vessel.
Two patients with ST-related SB occlusions (both Type A
diagonal branches) had non–Q wave infarctions. In both
cases, the SB (not previously protected) was treated after its
occlusion (prolonged angina and ST segment changes),
eventually with angiographic success. Although these pa-
tients were asymptomatic when they left the hemodynamic
room, both developed mild (390 and 480 IU of creatinine
kinase) enzymatic changes.
Side-branch changes. Of the 226 ST-related SB, 94 (42%)
were $1 mm, 101 (45%) had associated ostial disease
(21 mild, 38 moderate, 42 severe), 80 (35%) had an
unfavorable (angulated) takeoff, and 42 (18%) were located
near (#3 mm) the ST margins. Twenty-four SB (10%)
became occluded after the intervention (Figs. 1 and 2), and
in 57 (25%) a deterioration in anterograde flow ($1 TIMI
flow grade) was documented. In three patients with severe
in-ST restenosis, improvement in SB flow was seen after
intervention. The fate of SB in relation to SB type and
classification is presented in Figure 3. Side-branch occlusion
was seen in 20 cases (20%) with versus 4 (3%) cases without
ostial involvement (p , 0.001). Any severity of ostial disease
was related to this adverse outcome.
The influence of different clinical, procedural and ana-
tomic variables on SB changes is presented in Figure 4. On
logistic regression analysis, SB occlusion at the time of
initial stenting, diabetes, SB ostial involvement, SB TIMI
flow grade ,3, and restenosis length were identified as
independent predictors of SB occlusion. The influence of
balloon/artery ratio, however, disappeared after adjustment.
This model had a sensitivity of 83.3% and a specificity of
79.3% to predict SB occlusion. The probability of SB
occlusion within the model was 38.5% when both ostial
disease and TIMI flow grade ,3 were present (18 SB) and
only 2.6% when none of these factors was found (112 SB).
When prior SB occlusion at initial stenting was added to the
presence of TIMI flow grade ,3 and ostium disease (16
SB), the probability of occlusion increased to 65% (vs. only
1% when none of these three factors were present). In
addition, although use of device (other than balloon) and
adverse SB angulation were associated with SB flow dete-
rioration (Fig. 4, bottom), this was no longer seen after
adjustment. Of the 24 SB that became occluded, 10 (41%)
also had suffered occlusion (TIMI flow grade 0–1, without
enzymatic changes or any clinical sequelae) during initial ST
implantation (Table 3). Furthermore, late angiography was
available in 19 of the 24 occluded SB, revealing that 17
(89%) were again patent (Figs. 1 and 2).
Clinical and angiographic follow-up. Late clinical
follow-up (mean 21 6 18 months, range 3 to 102 months)
was obtained in all (100%) patients. During this time three
patients died (all noncardiac causes), none suffered a myo-
cardial infarction, and 24 patients required revascularization
(20 coronary angioplasty [14 target site, 6 other site] and
4 coronary surgery). The event-free survival at two years was
similar for patients with and without SB occlusion (81% vs.
82%; NS). In addition, recurrent restenosis rate (with a 74%
rate of late angiography in eligible patients) was docu-
mented in 33/70 (47%) patients; again, this was not influ-
enced by the previous occurrence of SB occlusion.
DISCUSSION
Interventional catheter-based therapy has been revolution-
ized by the widespread use of coronary ST (1–5). Conse-
quently, in-ST restenosis has become a major clinical
problem affecting an increasing number of patients (6–17).
Histopathologic studies have demonstrated that in-ST re-
stenosis results from smooth muscle cell hyperplasia (28),
whereas intravascular ultrasound has confirmed that in-ST
restenosis is caused by soft tissue growth within the ST,
without significant changes of the metallic struts (29,30).
Conventional balloon angioplasty has been used for many
years in patients presenting with ST restenosis (6–9). This
technique is readily performed and is associated with good
initial clinical and angiographic results (6–9). Additional
ST expansion and tissue extrusion out of the ST struts
contribute to the lumen enlargement obtained with balloon
dilation (29). However, some of these patients, in particular
those with diffuse in-ST restenosis, have relatively high
Figure 1. Angiogram in the left anterior oblique projection with cranial
angulation showing a restenosed stent in the proximal left anterior
descending coronary artery (a). The distal part of the stent spanned a
disease-free septal branch (Type B) and a diagonal branch (arrow) with
ostial involvement (Type A). After treatment (b) a good angiographic
result was obtained in the left anterior descending coronary artery (parent
vessel); the septal branch remained patent but the diagonal branch became
occluded (asterisk). This occlusion was clinically silent. The six-month
angiogram (c) revealed an adequate angiographic result on the left anterior
descending coronary artery and patency (reappearance) of the diagonal
branch (arrow).
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recurrent restenosis rate (11,12). In this setting, removal of
the intra-ST proliferative material with debulking tech-
niques has been advocated to optimize final results and
reduce the restenosis rate (10–12). More recently, great
enthusiasm has been generated by the use of brachytherapy
to prevent recurrent restenosis (13). Nevertheless, despite
the large interest focused on clinical research in patients
with in-ST restenosis, no information is yet available
concerning the incidence, predictive factors and clinical
implications of SB occlusion in this cohort of patients.
Outcome of side branches after balloon angioplasty and
initial stenting. Side-branch occlusion during conven-
tional coronary angioplasty is a well-described phenomenon
occurring in up to 10% of patients (14,15). Potential
mechanisms include displacement of atheromatous plaque
to the ostium of the SB, embolization of atheromatous
debris, thrombus formation, spasm and vessel dissection.
The SB with proximal disease are particularly prone to
experience occlusion after balloon dilation, being the clinical
consequence directly related to SB vessel diameter (14,15).
Stent implantation may further jeopardize SB patency.
Side-branch occlusion after ST implantation is also rela-
tively frequent and a benign event (16–20). In many of these
patients, SB occlusions occur during balloon predilation but
also may be seen either during ST deployment or after
high-pressure optimization. In addition to the above-
Figure 2. Left panel. Angiogram in the right anterior oblique projection revealing a severe stenosis in the mid-left anterior descending coronary artery. (a)
De novo lesion. (b) After initial stenting. (c) Stent restenosis (before treatment). (d) Immediately after treatment of in-stent restenosis (index procedure).
(e) At six-month follow-up. A large diagonal branch and two small septal perforator side branches are always visualized. Right panel. Angiogram in the
left anterior oblique projection with cranial angulation in a patient with a tight lesion in the proximal left anterior descending coronary artery (a to e, timing
same as above). A diagonal branch—with severe ostium involvement—remained patent after initial stenting, occluded (without clinical sequelae) during
treatment of in-stent restenosis (asterisk) and reappeared at follow-up (arrow).
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described mechanisms occurring during balloon dilation, SB
occlusion may result from partial or complete blockage of
the SB by the ST struts (16,17). Finally, longitudinal
redistribution of atherosclerotic plaque during high-pressure
ST deployment in the parent vessel may contribute to the
classic “snowplow” effect (20). In any case, the more
aggressive dilation of the vessel during stenting is likely
implicated.
Many factors appear to enhance the likelihood of SB
occlusion during stenting. First, ostium involvement of the
SB has been identified in most previous studies as a reliable
predictor of SB occlusion (16–20). Second, it has been
suggested that ST indication may also play a role because
ST implanted to seal major vessel dissections are associated
with a higher incidence of SB occlusion. In particular, SB
arising within the dissecting plane are prone to occlusion
(18). Finally, some investigators have suggested that some
ST designs may offer particular advantages in patients with
major SB who are to undergo ST implantation (18). The
ratio of metal to free spaced area in the fully deployed ST
can be also an important factor (16–18).
Most series have suggested that SB occlusion after
stenting is a benign event. Spontaneous recanalization of the
initially occluded SB may explain, at least in part, the low
rate of adverse events. However, of particular concern is that
ST placement across the SB results in the “stent jail”
phenomenon, which may be clinically relevant when large
SB require treatment. However, the inaccessibility to an-
gioplasty catheters is only relative. Although “stent jail”
limits interventional access to the compromised branch and
the procedure is technically demanding, it appears to be safe
and effective in up to 84% of patients (20). The ST-related
SB may be easily dilated when they emerge from coil stents,
but dilation through the ST diamonds in slotted-tube
designs may be more challenging. Special care should be
taken before dilation to know ST-diamond perimeter in
order to select appropriate balloon diameters and avoid
balloon rupture or entrapment. Moreover, during SB treat-
ment one should always bear in mind the importance of the
parent vessel, and every effort should be made to prevent any
deterioration in its lumen.
Present findings. The following are the major findings of
the present study: 1) repeat intervention in patients with
in-ST restenosis has a 10% risk of acute SB occlusion; 2)
most of these iatrogenic SB occlusions are clinically silent,
and this phenomenon does not appear to have acute or
long-term clinical implications; 3) although SB occlusion
remains a largely unpredictable event, special care should be
taken in patients with large SB that already became oc-
cluded during initial stenting and those SB with ostium
compromise or a deteriorated flow; patients with diabetes
Figure 3. Flow diagram illustrating the occurrence of side-branch (SB)
occlusion in relation to location (top) and SB classification (bottom).
RVB 5 right ventricular branch; PL 5 posterolateral branch; ST 5 stent. Figure 4. Clinical, procedural, and angiographic predictors of side-branch
(SB) occlusion (top) and of SB flow deterioration (bottom). Crude
(unadjusted) relative risks (RR) and confidence intervals (CI) are displayed
in a logarithmic scale. Adj RR 5 adjusted relative risks; Ad Hoc 5
procedures performed during the diagnostic coronary angiogram; Ostial-
D 5 ostial disease in the SB; R Length 5 restenosis length (studied per
1 mm of increment); B/A Ratio 5 balloon/artery ratio using quantitative
angiography (.1.13, upper tertile); Device 5 use of any device different
from balloon angioplasty; angle 5 adverse takeoff angulation of the SB;
MLD 5 minimal lumen diameter of the parent vessel after intervention
(per 1 mm of increment); ST1 5 during initial stenting.
1554 Alfonso et al. JACC Vol. 36, No. 5, 2000
Side Branches in Restenosed Stents November 1, 2000:1549–56
and those with diffuse restenosis are also at higher risk; and
4) most SB experiencing acute occlusion are patent at late
follow-up.
We found that patients that had experienced SB occlu-
sion during initial stent deployment had a 11-fold risk
increase for subsequent occlusion of the same SB during
repeat intervention for in-ST restenosis. In fact, this was the
strongest independent predictor for SB occlusion. We also
found a five-fold risk increase in SB with either preexisting
ostial disease or abnormal flow. All these findings, suggest-
ing a key role for anatomical factors, are in accordance with
results obtained after balloon dilation or initial stenting
(14–18). The presence of diffuse in-ST restenosis would in
turn enhance the likelihood of SB occlusion.
Finally, diabetes mellitus also emerges as an important
clinical risk factor, even after adjustment for other adverse
baseline characteristics frequently found in these patients,
such as vessel size. The influence of technical or procedural
factors, however, appears to be less dramatic. We were
unable to detect any protective effect of debulking tech-
niques on ST-related SB outcome. On the contrary, in our
series the use of devices other than balloons was associated
with a higher risk of flow deterioration in the SB spanned by
the ST, but this association disappeared after adjustment.
Therefore, this may reflect a selection bias, in that such
devices were more frequently used in complex cases. In fact,
careful observations regarding the exact timing of SB
occlusion during the procedure revealed that only a minority
of SB occlusions could be directly attributable to debulking
or repeat stenting itself. Furthermore, in our series some
technical data associated with a more aggressive interven-
tion (i.e., balloon/artery ratio, inflation pressures and final
lumen diameters) were related to SB flow changes on
univariate analysis. However, their influence on SB occlu-
sion disappears after adjustment.
We can only speculate as to the mechanism of SB
occlusion. However, potential mechanisms implicated in SB
occlusion in this setting appear to be largely the same as
those previously reported during dilation or ST implanta-
tion in de novo lesions. These include thrombus formation,
dissection, plaque embolization (debris), ostial compromise
by displaced ST struts and spasm at the ostium. However,
this latter circumstance appears unlikely because intracoro-
nary nitroglycerin was systematically given in our patients.
Intimal disruption involving the ostium of the SB may be
operative. Nevertheless, a special form of “snowplow effect”
manifested by both plaque remodeling and material sifting
along the cleavage plane provided by the underlying ST
appears as an attractive explanation, unique to this patho-
logic setting.
On the other hand, it is also important to keep in mind
the dynamic nature of the anatomopathologic changes
induced by balloon dilation of a restenosed ST. Extrusion of
neointimal material out of the ST struts may be facilitated
throughout a nearby SB, promoting its occlusion. However,
as recently demonstrated (30), significant acute lumen loss
occurs immediately after coronary interventions in patients
with in-ST restenosis. Neointimal tissue reintrusion back
into the ST seems to explain this early loss of lumen area
(30). These dynamic changes may be related to the flow
changes observed in the SB spanned by the ST and, more
importantly, could also explain its reappearance at follow-
up. Dissolution of thrombus, relief of spasm, or plaque
remodeling are alternative explanations.
Another important finding of the present study is that the
loss of a SB during repeat intervention for in-ST restenosis
was rarely associated with significant ischemic manifesta-
tions. Therefore, in-ST restenosis with small-to-moderate
size related SB should not preclude coronary intervention in
these patients. From a pragmatic point of view our findings
suggest that small (,1 mm) SB arising from a restenosed
ST may be disregarded when repeat intervention is being
planed. They are not associated with adverse events, and
they are not appropriate for revascularization. Conversely, in
selected patients with large SB at risk it may be wise to use
a double-wire technique. Should SB occlusion occur with or
without concomitant ischemic manifestations, dilation of
the occluded, ST-jailed SB could be readily attempted.
Study limitations. Our study group represents a series of
consecutive patients undergoing repeat coronary interven-
tion for in-ST restenosis. However, the number of major SB
spanned by the ST was relatively low, probably reflecting a
selection at the time of initial ST implantation. Neverthe-
less, this represents current clinical practice during coronary
stenting. In addition, the most appropriate technique to
prevent SB occlusion and the strategy best suited to dilated
SB jailed by the ST cannot be determined from our data and
are beyond the scope of this study. The same applies to the
management of in-ST restenosis after radical or complete
ST reconstruction of true bifurcated lesions (23).
Conclusions. Side-branch occlusion and flow deterioration
are relatively frequent during coronary intervention for
in-ST restenosis, but neither one is associated with an
adverse clinical outcome. Identification of threatened SB
Table 3. Side-Branch Occlusion: Initial Stenting versus Treatment of In-Stent Restenosis. SB Occlusion (TIMI flow grade 0) During
Intervention for In-ST Restenosis (n 5 24)*
Sensitivity Specificity 1LR (95% CI) 2LR (95% CI)
TIMI flow grade 0 ST1 (n 5 16) 17% 94% 2.81 (1.00–8.01) 0.89 (0.74–1.06)
TIMI flow grade 0–1 ST1 (n 5 24) 42% 93% 6.01 (3.00–12.02) 0.63 (0.45–0.88)
SB 5 side branch; TIMI 5 Thrombolysis in Myocardial Infarction coronary flow grade; LR 5 likelihood ratio; ST 5 stent; ST1 5 initial stent implantation; CI 5 confidence
intervals.
*Of the 24 SB with TIMI flow grade 0 during the index procedure, 10 had previously experienced occlusion during initial stenting (4 TIMI flow grade 0 and 6 TIMI flow
grade 1).
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morphology is challenging, but prior occlusion during initial
stenting, ostial disease, and compromised SB flow constitute
useful markers of vessels at jeopardy. The risk is also higher
in patients with diabetes and those with diffuse in-ST
restenosis. Therefore, it may be justifiable to take special
precautions in the management of large SB in patients with
these risk factors. Nevertheless, ST-related SB should not
preclude repeat percutaneous interventions in these patients.
Reprint requests and correspondence: Dr. Fernando Alfonso,
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